Occult bone marrow involvement in patients with diffuse large B‐cell lymphoma: results of a pilot study

References

• Australian Cancer Network Diagnosis and Management of Lymphoma Guidelines Working Party. Guidelines for the Diagnosis and Management of Lymphoma. The Cancer Council Australia and Australian Cancer Network, Sydney 2005
   Google Scholar
• Jaffe E. S., Harris N. E., Stein H., et al. The World Health Organization Classification of Tumours. Pathology and Genetics: Tumours of the Hematopoietic and Lymphoid Tissues. IARC Press, Lyon 2001
   Google Scholar
• The Haemato‐Oncology Task Force of British Committee for Standards in Haematology. BCSH Guidelines on Nodal Non‐Hodgkin's Lymphoma: Draft 2, August 2002. Blackwell Publishing, Oxford 2002
   Google Scholar
• Alizadeh A. A., Eisen M. B., Davis R. E., et al. Distinct types of diffuse large B‐cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–11
   PubMed Web of Science ®Google Scholar
• de Leval L., Harris N. L. Variability in immunophenotype in diffuse large B‐cell lymphoma and its clinical relevance. Histopathology 2003; 43: 509–28
   PubMed Web of Science ®Google Scholar
• Carbone P. P., Kaplan H. S., Musshoff K., et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860–1
   PubMed Web of Science ®Google Scholar
• Fisher R. I., Gaynor E. R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non‐Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–6
   PubMed Web of Science ®Google Scholar
• Sonneveld P., de Ridder M., Van der Lelie H., et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced non‐Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995; 13: 2530–9
   PubMed Web of Science ®Google Scholar
• Lambertenghi D. G., Butti C., Baldini L., et al. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisolone (CEOP) in non‐Hodgkin's lymphoma. Haematologica 1995; 80: 318–24
   PubMed Web of Science ®Google Scholar
• Goss P., Burkes R., Rudinskas L., et al. A phase II trial of prednisolone, oral Etoposide, and novantrone (PEN) as initial treatment of non‐Hodgkin's lymphoma in elderly patients. Leuk Lymphoma 1995; 18: 145–52
   PubMed Web of Science ®Google Scholar
• Lone S. W., Crawford J., Kenealy M., et al. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G‐CSF) supporting a dose‐intensive rapidly cycling anti‐metabolite containing chemotherapy regimen (hyper‐CVAD) for lymphoid malignancy. Leuk Lymphoma 2006; 47: 1813–7
   PubMed Web of Science ®Google Scholar
• Khaled H. M., Zekri Z. K., Mokhtar N., et al. A randomised EPOCH vs. CHOP front‐line therapy for aggressive non‐Hodgkin's lymphoma patients: long‐term results. Ann Oncol 1999; 10: 1489–92
   PubMed Web of Science ®Google Scholar
• Kingreen D., Beyer J., Kleiner S., et al. ICE – an efficient drug combination for stem cell mobilization and high‐dose treatment of malignant lymphoma. Eur J Haematol 2001; 64: 46–50
   Google Scholar
• Marti G. E., Rawstron A. C., Ghia P., et al. Diagnostic criteria for monoclonal B‐cell lymphocytosis. Br J Haematol 2005; 130: 325–32
   PubMed Web of Science ®Google Scholar
• van Dongen J. J., Langerak A. W., Bruggemann M., et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T‐cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED‐2 Concerted Action BMH4‐CT98‐3936. Leukemia 2003; 17: 2257–317
   PubMed Web of Science ®Google Scholar
• No authors listed. A predictive model for aggressive non‐Hodgkin's lymphoma. The International Non‐Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–94
   PubMed Web of Science ®Google Scholar
• Campbell J., Seymour J. F., Matthews J., Wolf M., Stone J., Juneja S. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol 2006; 76: 473–80
   PubMed Web of Science ®Google Scholar
• Nicolaides C., Fountzilas G., Zoumbos N., et al. Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non‐Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study. Oncology 1998; 55: 405–15
   PubMed Web of Science ®Google Scholar
• Yan Y., Chan W. C., Weisenburger D. D., et al. Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B‐cell lymphoma. J Clin Oncol 1995; 13: 1336–42
   PubMed Web of Science ®Google Scholar
• Benjamin D., Magrath I. T., Douglass E. C., et al. Derivation of lymphoma cell lines from microscopically normal bone marrow in patients with undifferentiated lymphomas: evidence of occult bone marrow involvement. Blood 1983; 61: 1017–9
   PubMed Web of Science ®Google Scholar
• Sah S. P., Matutes E., Wotherspoon A. C. A comparison of flow cytometry, bone marrow biopsy, and bone marrow aspirates in the detection of lymphoid infiltration in B cell disorders. J Clin Pathol 2003; 56: 129–32
   PubMed Web of Science ®Google Scholar
• Stacchini A., Demurtas A., Godio L., et al. Flow cytometry in the bone marrow staging of mature B‐cell neoplasms. Cytometry B Clin Cytom 2003; 54: 10–8
   PubMed Web of Science ®Google Scholar
• Duggan P. R., Easton D., Luider J., et al. Bone marrow staging of patients with non‐Hodgkin lymphoma by flow cytometry: correlation with morphology. Cancer 2000; 88: 894–9
   PubMed Web of Science ®Google Scholar
• Hanson C. A., Kurtin P. J., Katzmann J. A., et al. Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B‐cell malignant lymphoma. Blood 1999; 94: 3889–96
   PubMed Web of Science ®Google Scholar
• Perea G., Altes A., Bellido M., et al. Clinical utility of bone marrow flow cytometry in B‐cell non‐Hodgkin lymphomas (B‐NHL). Histopathology 2004; 45: 268–74
   PubMed Web of Science ®Google Scholar
• Chetty R., Echezarreta G., Comley M., et al. Immunohistochemistry in apparently normal bone marrow trephine specimens from patients with nodal follicular lymphoma. J Clin Pathol 1995; 48: 1035–8
   PubMed Web of Science ®Google Scholar
• Fraga M., Brousset P., Schlaifer D., et al. Bone marrow involvement in anaplastic large cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic significance. Am J Clin Pathol 1995; 103: 82–9
   PubMed Web of Science ®Google Scholar
• Coad J. E., Olson D. J., Christensen D. R., et al. Correlation of PCR‐detected clonal gene rearrangements with bone marrow morphology in patients with B‐lineage lymphomas. Am J Surg Pathol 1997; 21: 1047–56
   PubMed Web of Science ®Google Scholar
• Crotty P. L., Smith B. R., Tallini G. Morphologic, immunophenotypic, and molecular evaluation of bone marrow involvement in non‐Hodgkin's lymphoma. Diagn Mol Pathol 1998; 7: 90–5
   PubMedGoogle Scholar
• Maes B., Achten R., Demunter A., et al. Evaluation of B cell lymphoid infiltrates in bone marrow biopsies by morphology, immunohistochemistry, and molecular analysis. J Clin Pathol 2000; 53: 835–40
   PubMed Web of Science ®Google Scholar
• Mitterbauer‐Hohendanner G., Mannhalter C., Winkler K., et al. Prognostic significance of molecular staging by PCR‐amplification of immunoglobulin gene rearrangements in diffuse large B‐cell lymphoma (DLBCL). Leukemia 2004; 18: 1102–7
   PubMed Web of Science ®Google Scholar
• Juneja S. K., Wolf M. M., Cooper I. A. Value of bilateral bone marrow biopsy specimens in non‐Hodgkin’s lymphoma. J Clin Pathol 1990; 43: 630–2
   PubMed Web of Science ®Google Scholar
• Lassmann S., Gerlach U. V., Technau‐Ihling K., et al. Application of BIOMED‐2 primers in fixed and decalcified bone marrow biopsies: analysis of immunoglobulin H receptor rearrangements in B‐cell non‐Hodgkin's lymphomas. J Mol Diagn 2005; 7: 582–91
   PubMed Web of Science ®Google Scholar